Plain-English translation of NCT03942653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications— (a hormone therapy) and (an immunotherapy drug)—work better together to treat advanced salivary gland cancer than either might work alone. The study will enroll about 20 patients with salivary gland cancer that has spread or come back and cannot be removed surgically or treated with radiation. Researchers want to learn whether this medication combination can shrink or control tumors in people whose cancers have certain characteristics.
Salivary gland cancers that have spread are difficult to treat and have limited options once surgery and radiation are no longer possible. This trial exists to explore a new approach combining hormone therapy with immunotherapy, which works with your body's immune system to fight cancer cells.
You likely qualify if…
You likely don't qualify if…
You would receive injections under the skin every 4 weeks and infusions (through an IV) every 3 weeks, continuing for up to about 2 years or until your cancer progresses or side effects become too difficult. You would have CT scans of your neck, chest, abdomen, and pelvis every 12 weeks to monitor how your cancer is responding. A sample of your tumor tissue from a previous procedure would be analyzed, and an optional new biopsy might be performed after a few doses of medication to understand how your immune system is responding to treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States